Nov 20 (Reuters) - Mesoblast Ltd MSB.AX :
* QTRLY REVENUE US$1.3 MILLION VERSUS US$17 MILLION
* QTRLY LOSS ATTRIBUTABLE AT US$24.5 MILLION VERSUS US$5.5 MILLION
* ENTERED A LICENSE AND COLLABORATION AGREEMENT WITH NOVARTIS PHARMA AG
* WILL RECEIVE $50.0 MILLION IN PROCEEDS VIA PLACEMENT OF NEW MESOBLAST SHARES ON CLOSING OF LICENSE AGREEMENT